.

Deeper Knowledge, Faster

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

QuintilesIMS
Cantor Fitzgerald
Novartis
Citi
Accenture
Chinese Patent Office
Merck
Argus Health
UBS
Express Scripts

Generated: November 24, 2017

DrugPatentWatch Database Preview

Venetoclax - Generic Drug Details

« Back to Dashboard

What are the generic sources for venetoclax and what is the scope of venetoclax freedom to operate?

Venetoclax
is the generic ingredient in one branded drug marketed by Abbvie Inc and is included in one NDA. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Venetoclax has one hundred and five patent family members in thirty-nine countries and four supplementary protection certificates in four countries.

One supplier is listed for this compound.

Summary for venetoclax

Pharmacology for venetoclax

Drug ClassBCL-2 Inhibitor
Mechanism of ActionP-Glycoprotein Inhibitors
Physiological EffectIncreased Cellular Death
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbvie Inc
VENCLEXTA
venetoclax
TABLET;ORAL208573-002Apr 11, 2016RXYesNo► Subscribe► Subscribe► Subscribe
Abbvie Inc
VENCLEXTA
venetoclax
TABLET;ORAL208573-003Apr 11, 2016RXYesYes► Subscribe► SubscribeYY ► Subscribe
Abbvie Inc
VENCLEXTA
venetoclax
TABLET;ORAL208573-003Apr 11, 2016RXYesYes► Subscribe► Subscribe► Subscribe
Abbvie Inc
VENCLEXTA
venetoclax
TABLET;ORAL208573-001Apr 11, 2016RXYesNo► Subscribe► Subscribe► Subscribe
Abbvie Inc
VENCLEXTA
venetoclax
TABLET;ORAL208573-002Apr 11, 2016RXYesNo► Subscribe► Subscribe ► Subscribe
Abbvie Inc
VENCLEXTA
venetoclax
TABLET;ORAL208573-003Apr 11, 2016RXYesYes► Subscribe► Subscribe► Subscribe
Abbvie Inc
VENCLEXTA
venetoclax
TABLET;ORAL208573-003Apr 11, 2016RXYesYes► Subscribe► Subscribe ► Subscribe
Abbvie Inc
VENCLEXTA
venetoclax
TABLET;ORAL208573-002Apr 11, 2016RXYesNo► Subscribe► SubscribeYY ► Subscribe
Abbvie Inc
VENCLEXTA
venetoclax
TABLET;ORAL208573-001Apr 11, 2016RXYesNo► Subscribe► SubscribeYY ► Subscribe
Abbvie Inc
VENCLEXTA
venetoclax
TABLET;ORAL208573-002Apr 11, 2016RXYesNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: venetoclax

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,580,794Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases► Subscribe
9,045,475Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases► Subscribe
9,034,875Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: venetoclax

Country Document Number Estimated Expiration
TaiwanI501966► Subscribe
CroatiaP20151001► Subscribe
Serbia54234► Subscribe
New Zealand603463► Subscribe
Costa Rica20110632► Subscribe
Dominican RepublicP2011000367► Subscribe
HungaryE027698► Subscribe
TaiwanI561523► Subscribe
Peru03452012► Subscribe
Singapore175253► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: VENETOCLAX

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2017000031Germany► SubscribePRODUCT NAME: VENETOCLAX (VENCLYXTO); REGISTRATION NO/DATE: EU/1/16/1138 20161205
0873Netherlands► SubscribeDETAILS ASSIGNMENT: CHANGE OF OWNER(S), ASSIGNMENT
2017 00021Denmark► SubscribePRODUCT NAME: VENETOCLAX; REG. NO/DATE: EU/1/16/1138/001-007 20161207
2017015Lithuania► SubscribePRODUCT NAME: VENETOKLAKSAS; REGISTRATION NO/DATE: EU/1/16/1138 20161205
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Farmers Insurance
Cerilliant
US Army
Argus Health
Harvard Business School
Cipla
Citi
Fish and Richardson
Johnson and Johnson
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot